Chronic myeloid leukemia following chemotherapy with 5′-deoxy-5-fluorouridine for gastric cancer

Motohiro Tsuzuki; Kousuke Handa; Kiyoko Yamamoto; Akio Hasegawa; Yukiya Yamamoto; Masato Watanabe; Syuichi Mizuta; Fumio Maruyama; Masataka Okamoto; Nobuhiko Emi; Kohji Ezaki

doi:10.2169/internalmedicine.47.1072

Chronic myeloid leukemia following chemotherapy with 5′-deoxy-5-fluorouridine for gastric cancer

Motohiro Tsuzuki, Kousuke Handa, Kiyoko Yamamoto, Akio Hasegawa, Yukiya Yamamoto, Masato Watanabe, Syuichi Mizuta, Fumio Maruyama, Masataka Okamoto, Nobuhiko Emi, Kohji Ezaki

医学部・血液内科学

研究成果: ジャーナルへの寄稿 › 学術論文 › 査読

8 被引用数 (Scopus)

抄録

We report here a very rare case of chronic myeloid leukemia (CML) following long-term chemotherapy with 5′-deoxy-5-fluorouridine (5′-DFUR) for gastric cancer. A 69-year-old man was diagnosed with the chronic phase of CML. Six years previously, he underwent radical subtotal gastrectomy for gastric cancer, and was subsequently treated with oral anti-metabolite 5′-DFUR as adjuvant chemotherapy for 6 years. He was placed on imatinib therapy, and achieved a major molecular response 10 months after the initiation of therapy. This is the first reported case of therapy-related CML following 5′-DFUR treatment.

本文言語	英語
ページ（範囲）	1739-1741
ページ数	3
ジャーナル	Internal Medicine
巻	47
号	19
DOI	https://doi.org/10.2169/internalmedicine.47.1072
出版ステータス	出版済み - 2008

All Science Journal Classification (ASJC) codes

内科学

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.2169/internalmedicine.47.1072

他のファイルとリンク

引用スタイル

@article{463bf753e0e14b2f8252f10bec9f9a55,

title = "Chronic myeloid leukemia following chemotherapy with 5′-deoxy-5-fluorouridine for gastric cancer",

abstract = "We report here a very rare case of chronic myeloid leukemia (CML) following long-term chemotherapy with 5′-deoxy-5-fluorouridine (5′-DFUR) for gastric cancer. A 69-year-old man was diagnosed with the chronic phase of CML. Six years previously, he underwent radical subtotal gastrectomy for gastric cancer, and was subsequently treated with oral anti-metabolite 5′-DFUR as adjuvant chemotherapy for 6 years. He was placed on imatinib therapy, and achieved a major molecular response 10 months after the initiation of therapy. This is the first reported case of therapy-related CML following 5′-DFUR treatment.",

author = "Motohiro Tsuzuki and Kousuke Handa and Kiyoko Yamamoto and Akio Hasegawa and Yukiya Yamamoto and Masato Watanabe and Syuichi Mizuta and Fumio Maruyama and Masataka Okamoto and Nobuhiko Emi and Kohji Ezaki",

year = "2008",

doi = "10.2169/internalmedicine.47.1072",

language = "English",

volume = "47",

pages = "1739--1741",

journal = "Internal Medicine",

issn = "0918-2918",

publisher = "Japanese Society of Internal Medicine",

number = "19",

}

TY - JOUR

T1 - Chronic myeloid leukemia following chemotherapy with 5′-deoxy-5-fluorouridine for gastric cancer

AU - Tsuzuki, Motohiro

AU - Handa, Kousuke

AU - Yamamoto, Kiyoko

AU - Hasegawa, Akio

AU - Yamamoto, Yukiya

AU - Watanabe, Masato

AU - Mizuta, Syuichi

AU - Maruyama, Fumio

AU - Okamoto, Masataka

AU - Emi, Nobuhiko

AU - Ezaki, Kohji

PY - 2008

Y1 - 2008

N2 - We report here a very rare case of chronic myeloid leukemia (CML) following long-term chemotherapy with 5′-deoxy-5-fluorouridine (5′-DFUR) for gastric cancer. A 69-year-old man was diagnosed with the chronic phase of CML. Six years previously, he underwent radical subtotal gastrectomy for gastric cancer, and was subsequently treated with oral anti-metabolite 5′-DFUR as adjuvant chemotherapy for 6 years. He was placed on imatinib therapy, and achieved a major molecular response 10 months after the initiation of therapy. This is the first reported case of therapy-related CML following 5′-DFUR treatment.

AB - We report here a very rare case of chronic myeloid leukemia (CML) following long-term chemotherapy with 5′-deoxy-5-fluorouridine (5′-DFUR) for gastric cancer. A 69-year-old man was diagnosed with the chronic phase of CML. Six years previously, he underwent radical subtotal gastrectomy for gastric cancer, and was subsequently treated with oral anti-metabolite 5′-DFUR as adjuvant chemotherapy for 6 years. He was placed on imatinib therapy, and achieved a major molecular response 10 months after the initiation of therapy. This is the first reported case of therapy-related CML following 5′-DFUR treatment.

UR - http://www.scopus.com/inward/record.url?scp=56349110929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56349110929&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.47.1072

DO - 10.2169/internalmedicine.47.1072

M3 - Article

C2 - 18827427

AN - SCOPUS:56349110929

SN - 0918-2918

VL - 47

SP - 1739

EP - 1741

JO - Internal Medicine

JF - Internal Medicine

IS - 19

ER -

Chronic myeloid leukemia following chemotherapy with 5′-deoxy-5-fluorouridine for gastric cancer

抄録

All Science Journal Classification (ASJC) codes

UN SDG

文献へのアクセス

他のファイルとリンク

フィンガープリント

引用スタイル